Sulfonium-modified echinocandins reverse *Cryptococcus* resistance by membrane disruption and enhanced cell wall inhibition
Background
Fungal infections pose a significant global health threat, claiming millions of lives annually, particularly in immunocompromised individuals. A major challenge is the intrinsic resistance of Cryptococcus neoformans to existing antifungal classes like echinocandins, which primarily target cell wall biosynthesis by inhibiting glucan synthase. This resistance severely limits treatment options, necessitating the development of novel compounds or strategies to overcome these inherent defense mechanisms and broaden the spectrum of effective antifungals.
Study Design
Researchers performed sulfonium covalent modification on the natural pneumocandin B0 scaffold, generating novel derivatives. These compounds were then evaluated for their antifungal activity against various Candida species and Cryptococcus neoformans. Key assessments included minimum inhibitory concentration (MIC) values, analysis of fungal membrane permeability and depolarization, and the inhibitory effect on glucan synthase activity. The study also investigated the cell wall biosynthesis disruption, drug resistance potential, safety profiles, pharmacokinetic properties, and robust in vivo antifungal efficacy of lead compounds 3h and 5h.
Results
The sulfonium-modified echinocandin derivatives demonstrated potent activity against Candida species and, crucially, reversed the innate resistance of Cryptococcus neoformans, with MIC values reaching as low as 2 μg/mL. Structural modification significantly elevated fungal membrane permeability and induced membrane depolarization, indicating a novel mechanism of action. This modification also enhanced the inhibitory effect on glucan synthase and profoundly disturbed cell wall biosynthesis. Compounds 3h and 5h were identified as particularly promising, exhibiting low drug resistance potential, favorable safety profiles, and satisfactory pharmacokinetic properties. > In in vivo models, these lead compounds showed robust antifungal efficacy, underscoring their potential as novel therapeutic candidates.
Key Findings
- Sulfonium-modified echinocandins reversed Cryptococcus neoformans resistance, achieving MICs as low as 2 μg/mL.
- Structural modification elevated fungal membrane permeability and induced membrane depolarization.
- Modified compounds enhanced
glucan synthaseinhibition and disturbedcell wall biosynthesis. - Compounds 3h and 5h showed low drug resistance potential, favorable safety, and satisfactory pharmacokinetics.
- Lead compounds demonstrated robust in vivo antifungal efficacy.
Why It Matters
This research offers a compelling strategy to combat intrinsically resistant fungal pathogens like Cryptococcus neoformans, a critical unmet medical need. The chemical modification of existing antifungal scaffolds, like echinocandins, can unlock new mechanisms of action or overcome established resistance pathways. This approach could lead to novel antifungal candidates with broader spectrum activity and improved efficacy against drug-resistant strains. While preclinical, the favorable safety and pharmacokinetic profiles of compounds 3h and 5h suggest a promising path toward clinical translation, potentially expanding the arsenal against life-threatening fungal infections and improving outcomes for vulnerable patient populations.
echinocandins
cryptococcus-neoformans
antifungal
drug-resistance
membrane-disruption
cell-wall-inhibition
